Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP reduced its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 80.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,857,900 shares of the biopharmaceutical company's stock after selling 7,692,600 shares during the period. Two Sigma Advisers LP owned approximately 0.09% of Bristol-Myers Squibb worth $105,083,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Transce3nd LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at $28,000. Fairway Wealth LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $28,000. Comprehensive Financial Planning Inc. PA bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $34,000. Tacita Capital Inc bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $39,000. Finally, M Holdings Securities Inc. bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $39,000. 76.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on BMY shares. UBS Group reduced their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Argus upgraded Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Citigroup upped their price target on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $58.00.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.07% of the company's stock.

Bristol-Myers Squibb Trading Down 0.0%

Bristol-Myers Squibb stock traded down $0.01 during trading hours on Thursday, hitting $46.99. The company had a trading volume of 11,034,958 shares, compared to its average volume of 13,183,407. Bristol-Myers Squibb has a 1 year low of $39.35 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm has a market cap of $95.63 billion, a P/E ratio of -10.63, a P/E/G ratio of 2.07 and a beta of 0.39. The company has a 50-day moving average price of $52.31 and a two-hundred day moving average price of $55.83.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. During the same quarter in the previous year, the business posted ($4.40) EPS. The company's quarterly revenue was down 5.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Stockholders of record on Friday, April 4th were issued a $0.62 dividend. The ex-dividend date of this dividend was Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.28%. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.